Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023 ROR1-targeted CAR T-cell therapy designed to overcome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results